{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:38:15Z","timestamp":1793925495876,"version":"4.8.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12026-025-09728-0","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T07:03:28Z","timestamp":1766819008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From immunosuppression to immune reprogramming: is triptolide a potential \u201cimmune reset\u201d agent in autoimmune diseases?"],"prefix":"10.1007","volume":"73","author":[{"given":"Dehui","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"9728_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/d41573-024-00018-2","volume":"56","author":"S Colafrancesco","year":"2013","unstructured":"Colafrancesco S, Agmon-Levin N, Perricone C, Shoenfeld Y. Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle. Immunol Res. 2013;56:200\u20135.\u00a0https:\/\/doi.org\/10.1038\/d41573-024-00018-2.","journal-title":"Immunol Res"},{"key":"9728_CR2","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1172\/jci78088","volume":"125","author":"MD Rosenblum","year":"2015","unstructured":"Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125:2228\u201333.  https:\/\/doi.org\/10.1172\/jci78088.","journal-title":"J Clin Invest"},{"key":"9728_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/BOR.0000000000000594","volume":"31","author":"E Liu","year":"2019","unstructured":"Liu E, Perl A. Pathogenesis and treatment of autoimmune rheumatic diseases. Curr Opin Rheumatol. 2019;31:307\u201315. https:\/\/doi.org\/10.1097\/bor.0000000000000594.","journal-title":"Curr Opin Rheumatol"},{"key":"9728_CR4","doi-asserted-by":"publisher","unstructured":"Lahlou DAZ. Immunopathological findings in rheumatoid arthritis: A comprehensive review. Int J Pathol Sci. 2024;6(1):36\u201338.\u00a0https:\/\/doi.org\/10.33545\/26649063.2024.v6.i1a.20.","DOI":"10.33545\/26649063.2024.v6.i1a.20"},{"key":"9728_CR5","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.77777","volume-title":"The recent topics in genetic polymorphisms","author":"M Arfin","year":"2020","unstructured":"Arfin M, Al-Asmari A, Huraib GB. Al- Harthi. In: \u00c7al\u0131\u015fkan M, Erol O, \u00d6z GCC, editors. The recent topics in genetic polymorphisms. London: IntechOpen; 2020;48\u201356. https:\/\/doi.org\/10.5772\/intechopen.77777."},{"key":"9728_CR6","doi-asserted-by":"publisher","first-page":"1025343","DOI":"10.3389\/fimmu.2022.1025343","volume":"13","author":"P Lapierre","year":"2022","unstructured":"Lapierre P, Alvarez F. Type 2 autoimmune hepatitis: genetic susceptibility. Front Immunol. 2022;13.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2022.1025343","journal-title":"Front Immunol"},{"key":"9728_CR7","doi-asserted-by":"publisher","unstructured":"Song X, Liang H, Nan F, Chen W, Li J, He L, Cun Y, Li Z, Zhang W, Zhang D. Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets. MedComm (2020MedComm (2020); 2025;6(7):e70262.https:\/\/doi.org\/10.1002\/mco2.70262.","DOI":"10.1002\/mco2.70262"},{"key":"9728_CR8","doi-asserted-by":"publisher","unstructured":"Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review. Trop Med Infect Dis. 202;9(1):13. https:\/\/doi.org\/10.3390\/tropicalmed9010013.","DOI":"10.3390\/tropicalmed9010013"},{"key":"9728_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2007.10.004","volume":"19","author":"P Blanco","year":"2008","unstructured":"Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19:41\u201352.\u00a0https:\/\/doi.org\/10.1016\/j.cytogfr.2007.10.004.","journal-title":"Cytokine Growth Factor Rev"},{"key":"9728_CR10","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/eji.200838535","volume":"38","author":"KH Mills","year":"2008","unstructured":"Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol. 2008;38:2636\u201349. https:\/\/doi.org\/10.1002\/eji.200838535.","journal-title":"Eur J Immunol"},{"key":"9728_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70262","volume":"6","author":"X Song","year":"2025","unstructured":"Song X, Liang H, Nan F, Chen W, Li J, He L, Cun Y, Li Z, Zhang W, Zhang D. Autoimmune Diseases: molecular pathogenesis and therapeutic targets. MedComm. 2025;6. https:\/\/doi.org\/10.1002\/eji.200838535.","journal-title":"MedComm"},{"key":"9728_CR12","doi-asserted-by":"publisher","unstructured":"Song Y, Li J, Wu Y. Evolving Understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. Signal Transduct Target Therapy. 2024;9(263). https:\/\/doi.org\/10.1002\/eji.200838535.","DOI":"10.1002\/eji.200838535"},{"key":"9728_CR13","doi-asserted-by":"publisher","unstructured":"Zhang C, Weng Y, Wang H, Zhan S, Li C, Zheng D, Lin Q. A synergistic effect of triptolide and curcumin on rheumatoid arthritis by improving cell proliferation and inducing cell apoptosis via inhibition of the IL-17\/NF-\u03baB signaling pathway. Int Immunopharmacol. 2024;42:112953. https:\/\/doi.org\/10.1016\/j.intimp.2024.112953.","DOI":"10.1016\/j.intimp.2024.112953"},{"key":"9728_CR14","doi-asserted-by":"publisher","unstructured":"Yuan K, Li X, Lu Q, Zhu Q, Jiang H, Wang T, Huang G, Xu A. Application and Mechanisms of Triptolide in the Treatment of Inflammatory Diseases-A Review. Front Pharmacol. 2019;10:1469. https:\/\/doi.org\/10.3389\/fphar.2019.01469.","DOI":"10.3389\/fphar.2019.01469"},{"key":"9728_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12016-017-8610-y","volume":"53","author":"J Bystrom","year":"2017","unstructured":"Bystrom J, I Clanchy F, E Taher T, M Al-Bogami M, A Muhammad H, Alzabin S, Mangat P, S Jawad A, O Williams R, A Mageed R. Response to treatment with TNF\u03b1 inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF(+) T lymphocytes. Clin Rev Allergy Immunol. 2017;53:265\u201376.\u00a0https:\/\/doi.org\/10.1007\/s12016-017-8610-y.","journal-title":"Clin Rev Allergy Immunol"},{"key":"9728_CR16","doi-asserted-by":"publisher","unstructured":"Suda Y, Ikuta K, Hayashi S, Wada K, Anjiki K, Kamenaga T, Tsubosaka M, Kuroda Y, Nakano N, Maeda T, Tsumiyama K, Matsumoto T, Kuroda R, Matsubara T. Comparison of anti-inflammatory and anti-angiogenic effects of JAK inhibitors in IL-6 and TNF\u03b1-stimulated fibroblast-like synoviocytes derived from patients with RA. Sci Rep. 2025;15(9736).  https:\/\/doi.org\/10.1038\/s41598-025-94894-2.","DOI":"10.1038\/s41598-025-94894-2"},{"key":"9728_CR17","doi-asserted-by":"publisher","unstructured":"Wang K, Luo H, Liu L, Gao H, Song Y, Li D. Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis. Front Pharmacol. 2025;16\u20132025. https:\/\/doi.org\/10.3389\/fphar.2025.1577628.","DOI":"10.3389\/fphar.2025.1577628"},{"key":"9728_CR18","doi-asserted-by":"publisher","unstructured":"Onishi M, Tanaka T, Fujii T, Murata K, Murakami K, Hashimoto M, Watanabe R, Nozaki Y, Ashida C, Yamamoto W, Yamada H, Sendo S, Ebina K, Makino H, Son Y, Wada Y, Hata K, Matsuda S, Morinobu A. Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg\/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther. 2025;27(52).https:\/\/doi.org\/10.1186\/s13075-025-03514-x.","DOI":"10.1186\/s13075-025-03514-x"},{"key":"9728_CR19","doi-asserted-by":"publisher","unstructured":"Miyazaki Y, Nakayamada S, Tanaka H, Hanami K, Fukuyo S, Kubo S, Yamaguchi A, Miyagawa I, Satoh-Kanda Y, Todoroki Y, Inoue Y, Ueno M, Tanaka Y. Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry. RMD Open. 2025;11(e004987). https:\/\/doi.org\/10.1136\/rmdopen-2024-004987.","DOI":"10.1136\/rmdopen-2024-004987"},{"key":"9728_CR20","doi-asserted-by":"publisher","unstructured":"Juanola X, Ramos MJM, Belzunegui JM, Fern\u00e1ndez-Carballido C, Gratac\u00f3s J. Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized Definition. Adv Ther 39, 1490\u20131501 (2022). https:\/\/doi.org\/10.1007\/s12325-022-02064-x.","DOI":"10.1007\/s12325-022-02064-x"},{"key":"9728_CR21","doi-asserted-by":"publisher","unstructured":"Lekpa FK, Poulain C, Wendling D, Soubrier M, De Bandt M, Berthelot JM, Gaudin P, Toussirot E, Goupille P, Pham T, Sellam J, Bruckert R, Paul M, Farrenq V, Claudepierre P. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther. 2012;14:R53.\u00a0https:\/\/doi.org\/10.1186\/ar3766.","DOI":"10.1186\/ar3766"},{"key":"9728_CR22","doi-asserted-by":"publisher","unstructured":"Yin Y, Wang M, Liu M, Zhou E, Ren T, Chang X, He M, Zeng K, Guo Y, Wu J. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Res Ther. 2020;22(111). https:\/\/doi.org\/10.1186\/s13075-020-02208-w.\u00a0","DOI":"10.1186\/s13075-020-02208-w"},{"key":"9728_CR23","doi-asserted-by":"publisher","unstructured":"Zhu LJ, Yang X, Yu XQ. Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010(465898). https:\/\/doi.org\/10.1155\/2010\/465898.","DOI":"10.1155\/2010\/465898"},{"key":"9728_CR24","doi-asserted-by":"publisher","unstructured":"Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. Frontiers in Immunology. 2015;6(550). https:\/\/doi.org\/10.3389\/fimmu.2015.00550.","DOI":"10.3389\/fimmu.2015.00550"},{"key":"9728_CR25","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1093\/rheumatology\/kead416","volume":"62","author":"D Nepal","year":"2023","unstructured":"Nepal D, Gazeley D. Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus. Rheumatology (Oxford). 2023;62:3804\u201310.\u00a0https:\/\/doi.org\/10.1136\/rmdopen-2024-004987.","journal-title":"Rheumatology (Oxford)"},{"key":"9728_CR26","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/ard.2007.077891","volume":"67","author":"NM Moutsopoulos","year":"2008","unstructured":"Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V, Pillemer S, Wahl SM. Lack of efficacy of etanercept in Sj\u00f6gren syndrome correlates with failed suppression of tumour necrosis factor \u03b1 and systemic immune activation. Ann Rheum Dis. 2008;67:1437\u201343. https:\/\/doi.org\/10.1136\/ard.2007.077891.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9728_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","volume":"126","author":"J Lin","year":"2008","unstructured":"Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNF\u03b1 blockade in human diseases: an overview of efficacy and safety. Clin Immunol. 2008;126(1):13\u201330.\u00a0https:\/\/doi.org\/10.1016\/j.clim.2007.08.012.","journal-title":"Clin Immunol"},{"key":"9728_CR28","doi-asserted-by":"publisher","unstructured":"Kovalenko A, Honov\u00e1 J, Vala M, Lu\u0148\u00e1k S, Fekete L, Hor\u00e1kov\u00e1 P, Dokl\u00e1dalov\u00e1 L, Kub\u00e1\u010d L, Weiter M. Effect of the Side Chains and Anode Material on Thermal Stability and Performance of Bulk-Heterojunction Solar Cells Using DPP(TBFu)2 Derivatives as Donor Materials. International Journal of Photoenergy. 2015;73491. https:\/\/doi.org\/10.1155\/2015\/734917.","DOI":"10.1155\/2015\/734917"},{"key":"9728_CR29","doi-asserted-by":"publisher","unstructured":"Saggini A, Chimenti S, Chiricozzi A. IL-6 as a druggable target in psoriasis: focus on pustular variants. J Immunol Res. 2014;2014(964069). https:\/\/doi.org\/10.1016\/j.clim.2007.08.012.","DOI":"10.1016\/j.clim.2007.08.012"},{"key":"9728_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/cei.13258","volume":"196","author":"SI Aqel","year":"2019","unstructured":"Aqel SI, Kraus EE, Jena N, Kumari V, Granitto MC, Mao L, Farinas MF, Zhao EY, Perottino G, Pei W, Lovett-Racke AE, Racke MK, Fuchs JR, Li C, Yang Y. Novel small molecule IL-6 inhibitor suppresses autoreactive Th17 development and promotes T(reg) development. Clin Exp Immunol. 2019;196:215\u201325.\u00a0https:\/\/doi.org\/10.1016\/j.clim.2007.08.012.","journal-title":"Clin Exp Immunol"},{"key":"9728_CR31","doi-asserted-by":"publisher","unstructured":"Shahini A, Shahini A. Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome. J Cell Commun Signal. 2023;17:55\u201374. https:\/\/doi.org\/10.1007\/s12079-022-00695-x.","DOI":"10.1007\/s12079-022-00695-x"},{"key":"9728_CR32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/d41573-024-00018-2","volume":"23","author":"R Al-Horani","year":"2024","unstructured":"Al-Horani R, Chui T, Hamad B. The pipeline and market for psoriasis drugs. Nat Rev Drug Discov. 2024;23:492\u20133. https:\/\/doi.org\/10.1007\/s12079-022-00695-x.","journal-title":"Nat Rev Drug Discov"},{"key":"9728_CR33","doi-asserted-by":"publisher","unstructured":"Kerschbaumer A, Smolen JS, Nash P, Doerner T, Dougados M, Fleischmann R, Geissler K, McInnes IB, Takeuchi T, Trauner M, Winthrop K, de Wit M, Boehncke W-H, Falzon L, van der Heijde D. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020;6:e001374. https:\/\/doi.org\/10.1136\/rmdopen-2020-001374.","DOI":"10.1136\/rmdopen-2020-001374"},{"key":"9728_CR34","doi-asserted-by":"publisher","unstructured":"Wright S, Hennessy C, Hester J, Issa F. Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation. Engineering. 2022;10:30\u201343. https:\/\/doi.org\/10.1016\/j.eng.2021.10.018.","DOI":"10.1016\/j.eng.2021.10.018"},{"key":"9728_CR35","doi-asserted-by":"publisher","unstructured":"Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious complications of biological and small molecule targeted Immunomodulatory therapies. Clin Microbiol Rev. 2020;33(3):e00035\u201319. https:\/\/doi.org\/10.1128\/CMR.00035-19.","DOI":"10.1128\/CMR.00035-19"},{"key":"9728_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/cells10030539","volume":"10","author":"J Ingruber","year":"2021","unstructured":"Ingruber J, Savic D, Steinbichler TB, Sprung S, Fleischer F, Glueckert R, Schweigl G, Skvortsova I-I, Riechelmann H, Dud\u00e1s J. KLF4, slug and EMT in head and neck squamous cell carcinoma. Cells. 2021;10:539. https:\/\/doi.org\/10.1016\/j.eng.2021.10.018.","journal-title":"Cells"},{"key":"9728_CR37","doi-asserted-by":"publisher","unstructured":"Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. Am J Clin Dermatol. 2022;23:433\u2013447. https:\/\/doi.org\/10.1007\/s40257-022-00679-y.","DOI":"10.1007\/s40257-022-00679-y"},{"key":"9728_CR38","doi-asserted-by":"publisher","unstructured":"Wang N, Min X, Ma N, Zhu Z, Cao B, Wang Y, Yong Q, Huang J, Li K. The Negative Impact of Triptolide on the Immune Function of Human Natural Killer Cells. Pharmaceuticals (Basel). 2023;16(3):458. https:\/\/doi.org\/10.3390\/ph16030458.","DOI":"10.3390\/ph16030458"},{"key":"9728_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12026-025-09723-5","volume":"6","author":"S Ziaei","year":"2016","unstructured":"Ziaei S, Halaby R. Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review. Avicenna J Phytomed. 2016;6:149\u201364. https:\/\/doi.org\/10.1007\/s12026-025-09723-5.","journal-title":"Avicenna J Phytomed"},{"key":"9728_CR40","doi-asserted-by":"publisher","unstructured":"Yan T, Wang Y, Hou Z, Song P, Wang P, Li J, Zheng J, Lv D. A comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases. Frontiers in Pharmacology. 2025;16:1592066. https:\/\/doi.org\/10.3389\/fphar.2025.1592066.","DOI":"10.3389\/fphar.2025.1592066"},{"key":"9728_CR41","doi-asserted-by":"publisher","unstructured":"He Q, Wu X, Shi Q. Triptolide Inhibits Th17 Response by Upregulating microRNA-204-5p and Suppressing STAT3 Phosphorylation in Psoriasis. Genetics Research. 2022;7468396. https:\/\/doi.org\/10.1155\/2022\/7468396.","DOI":"10.1155\/2022\/7468396"},{"key":"9728_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.119748","volume":"347","author":"H Wang","year":"2025","unstructured":"Wang H, Zou J, Li Y, Liu J, Guo F. Tripterygium glycoside tablets and triptolide alleviate experimental autoimmune encephalomyelitis mice involving the PACAP\/cAMP signaling pathway. J Ethnopharmacol. 2025;347. https:\/\/doi.org\/10.1155\/2022\/7468396.","journal-title":"J Ethnopharmacol"},{"key":"9728_CR43","doi-asserted-by":"publisher","unstructured":"Shan Y, Zhao J, Wei K, Jiang P, Xu L, Chang C, Xu L, Shi Y, Zheng Y, Bian Y, Zhou M, Schrodi SJ, Guo S, He D. A comprehensive review of Tripterygium wilfordii hook. f. in the treatment of rheumatic and autoimmune diseases: Bioactive compounds, mechanisms of action, and future directions. Frontiers in Pharmacology. 2023;14:1282610. https:\/\/doi.org\/10.3389\/fphar.2023.1282610.","DOI":"10.3389\/fphar.2023.1282610"},{"key":"9728_CR44","doi-asserted-by":"publisher","unstructured":"Guo L, Yang Y, Ma J, Xiao M, Cao R, Xi Y, Li T, Huang T, Yan M. Triptolide induces hepatotoxicity by promoting ferroptosis through Nrf2 degradation. Cell Biol Toxicol. 2024;40:94. https:\/\/doi.org\/10.1007\/s10565-024-09930-0.","DOI":"10.1007\/s10565-024-09930-0"},{"key":"9728_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.freeradbiomed.2022.06.009","volume":"188","author":"J Lu","year":"2022","unstructured":"Lu J, Zhang Y, Dong H, Sun J, Zhu L, Liu P, Wen F, Lin R. New mechanism of nephrotoxicity of triptolide: oxidative stress promotes cGAS-STING signaling pathway. Free Radic Biol Med. 2022;188:26\u201334. https:\/\/doi.org\/10.1007\/s10565-024-09930-0.","journal-title":"Free Radic Biol Med"},{"key":"9728_CR46","doi-asserted-by":"publisher","unstructured":"Zhao J, Cao M, Yi H, He G, Chen T, Liu L, Guo K, Cao Y, Li C, Zhou X, Zhang B, Wang H. Triptolide Causes Spermatogenic Disorders by Inducing Apoptosis in the Mitochondrial Pathway of Mouse Testicular Spermatocytes. Toxics. 2024;12(12):896. https:\/\/doi.org\/10.3390\/toxics1212089.","DOI":"10.3390\/toxics1212089"},{"key":"9728_CR47","doi-asserted-by":"publisher","unstructured":"Tong L, Zhao Q, Datan E, Lin G-Q, Minn I, Pomper MG, Yu B, Romo D, He Q-L, Liu JO. Triptolide: reflections on two decades of research and prospects for the future. Natural Product Reports. 2021;8838(4);843\u2013860.https:\/\/doi.org\/10.1039\/D0NP00054J.","DOI":"10.1039\/D0NP00054J"},{"key":"9728_CR48","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.toxlet.2014.08.017","volume":"230","author":"J Zhou","year":"2014","unstructured":"Zhou J, Xi C, Wang W, Fu X, Jinqiang L, Qiu Y, Jin J, Xu J, Huang Z. Triptolide-induced oxidative stress involved with Nrf2 contribute to cardiomyocyte apoptosis through mitochondrial dependent pathways. Toxicol Lett. 2014;230:454\u201366. https:\/\/doi.org\/10.1039\/D0NP00054J.","journal-title":"Toxicol Lett"},{"key":"9728_CR49","doi-asserted-by":"publisher","unstructured":"Wang X, Zhang X, Liu F, Wang M, Qin S. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. Pharm Biol. 2017;55(1):1863\u20131867. https:\/\/doi.org\/10.1080\/13880209.2017.1340963.","DOI":"10.1080\/13880209.2017.1340963"},{"key":"9728_CR50","doi-asserted-by":"publisher","unstructured":"Hou W, Liu B, Xu H. Triptolide: Medicinal chemistry, chemical biology and clinical progress. Eur J Med Chem. 2019, 176, 378\u2013392. https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.032.","DOI":"10.1016\/j.ejmech.2019.05.032"},{"key":"9728_CR51","doi-asserted-by":"publisher","unstructured":"Gao J, Zhang Y, Liu X, Wu X, Huang L, Gao W. Triptolide: pharmacological spectrum, biosynthesis, chemical synthesis and derivatives. Theranostics. 2021;11:7199\u20137221.\u00a0https:\/\/doi.org\/10.7150\/thno.57745.","DOI":"10.7150\/thno.57745"},{"key":"9728_CR52","doi-asserted-by":"publisher","unstructured":"Tang W, Zuo JP. Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8). Acta Pharmacol Sin. 2012;33:1112\u20131118. https:\/\/doi.org\/10.1038\/aps.2012.108.","DOI":"10.1038\/aps.2012.108"},{"key":"9728_CR53","doi-asserted-by":"publisher","unstructured":"Cheng Y, Zhao Y, Zheng Y. Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity. Chin Med. 2021;16:114.\u00a0https:\/\/doi.org\/10.1186\/s13020-021-00525-z.","DOI":"10.1186\/s13020-021-00525-z"},{"key":"9728_CR54","doi-asserted-by":"publisher","unstructured":"Wang X, Ni T, Miao J, Huang X, Feng Z. The role and mechanism of triptolide, a potential new DMARD, in the treatment of rheumatoid arthritis. Ageing Res Rev. 2025;104:102643. https:\/\/doi.org\/10.1016\/j.arr.2024.102643.","DOI":"10.1016\/j.arr.2024.102643"},{"key":"9728_CR55","doi-asserted-by":"publisher","unstructured":"Gorrie D, Bravo M, Fan L. The Yin and Yang of the Natural Product Triptolide and Its Interactions with XPB, an Essential Protein for Gene Expression and DNA Repair. Genes (Basel). 2024;15. https:\/\/doi.org\/10.3390\/genes15101287.","DOI":"10.3390\/genes15101287"},{"key":"9728_CR56","doi-asserted-by":"publisher","unstructured":"Zhou GL, Su SL, Yu L, Shang EX, Hua YQ, Yu H, Duan JA. Exploring the liver toxicity mechanism of Tripterygium wilfordii extract based on metabolomics, network pharmacological analysis and experimental validation. J Ethnopharmacol. 2025;337:118888. https:\/\/doi.org\/10.1016\/j.jep.2024.118888.","DOI":"10.1016\/j.jep.2024.118888"},{"key":"9728_CR57","doi-asserted-by":"publisher","unstructured":"Wang Y, Jia L, Wu CY. Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis. Scand J Immunol. 2008;68:383\u201339.\u00a0https:\/\/doi.org\/10.1111\/j.1365-3083.2008.02147.x.","DOI":"10.1111\/j.1365-3083.2008.02147.x"},{"key":"9728_CR58","doi-asserted-by":"publisher","unstructured":"Chen Y, Liu Z, Yu Q, Qu X, Liu H. Integrating network pharmacology and experimental verification to explore the mechanism of Tripterygium wilfordii in ankylosing spondylitis. Medicine (Baltimore).\u00a02023;102:e36580.\u00a0https:\/\/doi.org\/10.1097\/md.0000000000036580.","DOI":"10.1097\/md.0000000000036580"},{"key":"9728_CR59","doi-asserted-by":"publisher","unstructured":"He Q, Wu X, Shi Q. Triptolide Inhibits Th17 Response by Upregulating microRNA-204-5p and Suppressing STAT3 Phosphorylation in Psoriasis. Genet Res (Camb). 2022;7468396.  https:\/\/doi.org\/10.1155\/2022\/7468396.","DOI":"10.1155\/2022\/7468396"},{"key":"9728_CR60","doi-asserted-by":"publisher","unstructured":"Zhao X, Ji W, Lu Y, Liu W, Guo F. Triptolide regulates the balance of Tfr\/Tfh in lupus mice.\u00a0Adv Rheumatol. 2023;63:29.\u00a0https:\/\/doi.org\/10.1186\/s42358-023-00311-5.","DOI":"10.1186\/s42358-023-00311-5"},{"key":"9728_CR61","doi-asserted-by":"publisher","unstructured":"Zhao X, Tang X, Yan Q, Song H, Li Z, Wang D, Chen H, Sun L. Triptolide ameliorates lupus via the induction of miR-125a-5p mediating Treg upregulation. Int Immunopharmacol. 2019;71:14\u201321.\u00a0https:\/\/doi.org\/10.1016\/j.intimp.2019.02.047.","DOI":"10.1016\/j.intimp.2019.02.047"},{"key":"9728_CR62","doi-asserted-by":"publisher","unstructured":"Fu YF, Zhu YN, Ni J, Zhong XG, Tang W, Zhou R, Zhou Y, Dong JR, He PL, Wan H, Li YC, Yang YF, Zuo JP. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation. J Neuroimmunol. 2006;175: 142\u2013151.https:\/\/doi.org\/10.1016\/j.jneuroim.2006.03.011.","DOI":"10.1016\/j.jneuroim.2006.03.011"},{"key":"9728_CR63","doi-asserted-by":"publisher","unstructured":"Zhang LY, Li H, Wu YW, Cheng L, Yan YX, Yang XQ, Zhu FH, He SJ, Tang W, Zuo JP. (5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL\/lpr mice by preventing infiltration of immune cells. Am J Physiol Renal Physiol. 2017;312:F769\u2013f777. https:\/\/doi.org\/10.1152\/ajprenal.00649.201.","DOI":"10.1152\/ajprenal.00649.201"},{"key":"9728_CR64","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.transproceed.2005.02.084","volume":"37","author":"O Fisniku","year":"2005","unstructured":"Fisniku O, Pan F, Wynn C, Erickson LM, Crews G, Jang MS, Sudo Y, Tamura K, Kobayashi M, Benediktsson H, Jiang H. Protective effects of PG490-88 on chronic allograft rejection by changing intragraft gene expression profiles. Transplant Proc. 2005;37:1962\u20134. https:\/\/doi.org\/10.1016\/j.transproceed.2005.02.084.","journal-title":"Transplant Proc"},{"key":"9728_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107472","volume":"94","author":"J Fu","year":"2021","unstructured":"Fu J, Zang Y, Zhou Y, Chen C, Shao S, Shi G, Wu L, Zhu G, Sun T, Zhang D, Zhang T. Exploring a novel triptolide derivative possess anti-colitis effect via regulating T cell differentiation. Int Immunopharmacol. 2021;94. https:\/\/doi.org\/10.1016\/j.transproceed.2005.02.084.","journal-title":"Int Immunopharmacol"},{"key":"9728_CR66","unstructured":"Dan S. Study on anti-tumor pharmacodynamics and mechanism of action of MC002, triptolide derivative (Chinese). China Acad Chin Med Sci, (2009)."},{"key":"9728_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.952775","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang F, Gao Y, Wang M, Gao Y, Li H, Sun J, Wen C, Xie Z. Triptolide in the treatment of systemic lupus erythematosus - regulatory effects on miR-146a in B cell TLR7 signaling pathway in mice. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.9527753.","journal-title":"Front Pharmacol"},{"issue":"3","key":"9728_CR68","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.bbrc.2006.05.024","volume":"345","author":"Q Liu","year":"2006","unstructured":"Liu Q, Chen T, Chen G, Li N, Wang J, Ma P, Cao X. Immunosuppressant triptolide inhibits dendritic cell-mediated chemoattraction of neutrophils and T cells through inhibiting Stat3 phosphorylation and NF-\u03baB activation. Biochem Biophys Res Commun. 2006;345(3):1122\u201330. https:\/\/doi.org\/10.1016\/j.bbrc.2006.05.024.","journal-title":"Biochem Biophys Res Commun"},{"key":"9728_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176201","volume":"962","author":"X Dong","year":"2024","unstructured":"Dong X, Zhu LW, Zhang Z, Cao R, Liu P, Shu X, Cao X, Hu Y, Bao X, Xu L, Li C, Xu Y. LLDT-8 ameliorates experimental autoimmune encephalomyelitis by mediating macrophage functions in the priming stage. Eur J Pharmacol. 2024;962. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176201.","journal-title":"Eur J Pharmacol"},{"key":"9728_CR70","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.molimm.2018.06.012","volume":"101","author":"G Huang","year":"2018","unstructured":"Huang G, Yuan K, Zhu Q, Zhang S, Lu Q, Zhu M, Sheng H, Yu R, Luo G, Xu A. Triptolide inhibits the inflammatory activities of neutrophils to ameliorate chronic arthritis. Mol Immunol. 2018;101:210\u201320. https:\/\/doi.org\/10.1016\/j.molimm.2018.06.012.","journal-title":"Mol Immunol"},{"key":"9728_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077513","volume":"8","author":"X Kong","year":"2013","unstructured":"Kong X, Zhang Y, Liu C, Guo W, Li X, Su X, Wan H, Sun Y, Lin N. Anti-angiogenic effect of triptolide in rheumatoid arthritis by targeting angiogenic cascade. PLoS One. 2013;8. https:\/\/doi.org\/10.1371\/journal.pone.0077513.","journal-title":"PLoS One"},{"issue":"1","key":"9728_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41514-6","volume":"13","author":"A Al-Roub","year":"2023","unstructured":"Al-Roub A, Akhter N, Al-Rashed F, Wilson A, Alzaid F, Al-Mulla F, Sindhu S, Ahmad R. TNF\u03b1 induces matrix metalloproteinase-9 expression in monocytic cells through ACSL1\/JNK\/ERK\/NF-kB signaling pathways. Sci Rep. 2023;13(1). https:\/\/doi.org\/10.1038\/s41598-023-41514-6.","journal-title":"Sci Rep"},{"key":"9728_CR73","doi-asserted-by":"publisher","unstructured":"Lin JJ, Tao K, Gao N, Zeng H, Wang DL, Yang J, Weng J. Triptolide Inhibits Expression of Inflammatory Cytokines and Proliferation of Fibroblast-like Synoviocytes Induced by IL-6\/sIL-6R-Mediated JAK2\/STAT3 Signaling Pathway. Curr Med Sci. 2021;41:133\u2013139. https:\/\/doi.org\/10.1007\/s11596-020-2302-1.","DOI":"10.1007\/s11596-020-2302-1"},{"key":"9728_CR74","doi-asserted-by":"publisher","unstructured":"Wen J, Liu J, Wang X, Wang J. Triptolide promotes the apoptosis and attenuates the inflammation of fibroblast-like synoviocytes in rheumatoid arthritis by down-regulating lncRNA ENST00000619282. Phytother Res\u00a02021;35:4334\u20134346. https:\/\/doi.org\/10.1002\/ptr.7129.","DOI":"10.1002\/ptr.7129"},{"key":"9728_CR75","doi-asserted-by":"publisher","unstructured":"Piao X, Zhou J, Xue L. Triptolide decreases rheumatoid arthritis fibroblast-like synoviocyte proliferation, invasion, inflammation and presents a therapeutic effect in collagen-induced arthritis rats via inactivating lncRNA RP11-83J16.1 mediated URI1 and \u03b2-catenin signaling. Int Immunopharmacol. 2021;99:108010. https:\/\/doi.org\/10.1002\/ptr.712910.1016\/j.intimp.2021.108010.","DOI":"10.1002\/ptr.712910.1016\/j.intimp.2021.108010"},{"key":"9728_CR76","doi-asserted-by":"publisher","unstructured":"Yang Y, Ye Y, Qiu Q, Xiao Y, Huang M, Shi M, Liang L, Yang X, Xu H. Triptolide inhibits the migration and invasion of rheumatoid fibroblast-like synoviocytes by blocking the activation of the JNK MAPK pathway. Int Immunopharmacol.\u00a02016;41:8\u201316. https:\/\/doi.org\/10.1016\/j.intimp.2016.10.005.","DOI":"10.1016\/j.intimp.2016.10.005"},{"key":"9728_CR77","doi-asserted-by":"publisher","unstructured":"Zhou X, Xie D, Huang J, Lu A, Wang R, Jin Y, Zhang R, Chang C, Xu L, Xu L, Fan J, Liang C, He D. Therapeutic Effects of (5R)-5-Hydroxytriptolide on Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via lncRNA WAKMAR2\/miR-4478\/E2F1\/p53 Axis. Front Immunol. 2021;12:605616.\u00a0 https:\/\/doi.org\/10.3389\/fimmu.2021.605616.","DOI":"10.3389\/fimmu.2021.605616"},{"key":"9728_CR78","doi-asserted-by":"publisher","unstructured":"Guo S, Liu J, Jiang T, Lee D, Wang R, Zhou X, Jin Y, Shen Y, Wang Y, Bai F, Ding Q, Wang G, Zhang J, Zhou X, Schrodi SJ, He D. (5R)-5-Hydroxytriptolide (LLDT-8) induces substantial epigenetic mediated immune response network changes in fibroblast-like synoviocytes from rheumatoid arthritis patients. Sci Rep.\u00a02019;9:11155. https:\/\/doi.org\/10.1038\/s41598-019-47411-1.","DOI":"10.1038\/s41598-019-47411-1"},{"key":"9728_CR79","doi-asserted-by":"publisher","unstructured":"Wang G, Cai J, Zhang J, Li C. Mechanism of triptolide in treating ankylosing spondylitis through the anti\u2013ossification effect of the BMP\/Smad signaling pathway. Mol Med Rep.\u00a02018;17:2731\u20132737. https:\/\/doi.org\/10.3892\/mmr.2017.8117.","DOI":"10.3892\/mmr.2017.8117"},{"key":"9728_CR80","doi-asserted-by":"publisher","unstructured":"Ji W, Liu S, Zhao X, Guo Y, Xia S, Lu Y, Yin M, Xu X. Triptolide inhibits proliferation, differentiation and induces apoptosis of osteoblastic MC3T3\u2013E1 cells. Mol Med Rep.\u00a02017;16:7391\u20137397. https:\/\/doi.org\/10.3892\/mmr.2017.7568.","DOI":"10.3892\/mmr.2017.7568"},{"key":"9728_CR81","doi-asserted-by":"publisher","unstructured":"Ji W, Lu Y, Ma Z, Gan K, Liu Y, Cheng Y, Xu J, Liu S, Guo Y, Han S, Zhao Z, Xu H, Qi W. Triptolide attenuates inhibition of ankylosing spondylitis-derived mesenchymal stem cells on the osteoclastogenesis through modulating exosomal transfer of circ-0110634. J Orthop Translat.\u00a02022;36:132\u2013144. hhttps:\/\/doi.org\/10.1016\/j.jot.2022.05.007.","DOI":"10.1016\/j.jot.2022.05.007"},{"key":"9728_CR82","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2125.2012.04221.x","volume":"74","author":"R Han","year":"2012","unstructured":"Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U. Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol. 2012;74:424\u201336. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04221.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9728_CR83","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.4238\/2014.April.29.12","volume":"13","author":"H Zhang","year":"2014","unstructured":"Zhang H, Zhang X, Ding X, Cao W, Qu L, Zhou G. Effect of secondary lymphoid tissue chemokine suppression on experimental ulcerative colitis in mice. Genet Mol Res. 2014;13(2):3337\u201345. https:\/\/doi.org\/10.4238\/2014.April.29.12.","journal-title":"Genet Mol Res"},{"key":"9728_CR84","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/j.molimm.2010.06.007","volume":"47","author":"Y Li","year":"2010","unstructured":"Li Y, Yu C, Zhu WM, Xie Y, Qi X, Li N, Li JS. Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6\/STAT3 signaling pathway and down-regulation of IL-17. Mol Immunol. 2010;47:2467\u201374. https:\/\/doi.org\/10.1016\/j.molimm.2010.06.007.","journal-title":"Mol Immunol"},{"issue":"1","key":"9728_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47411-1","volume":"9","author":"S Guo","year":"2019","unstructured":"Guo S, Liu J, Jiang T, Lee D, Wang R, Zhou X, Jin Y, Shen Y, Wang Y, Bai F, Ding Q, Wang G, Zhang J, Zhou X, Schrodi SJ, He D. (5R)-5-Hydroxytriptolide (LLDT-8) induces substantial epigenetic mediated immune response network changes in fibroblast-like synoviocytes from rheumatoid arthritis patients. Sci Rep. 2019;9(1). https:\/\/doi.org\/10.1038\/s41598-019-47411-1.","journal-title":"Sci Rep"},{"key":"9728_CR86","doi-asserted-by":"publisher","DOI":"10.3892\/br.2021.1457","volume":"15","author":"Y Li","year":"2021","unstructured":"Li Y, Qi W, Yan L, Wang M, Zhao L. Tripterygium wilfordii derivative LLDT-8 targets CD2 in the treatment of rheumatoid arthritis. Biomed Rep. 2021;15. https:\/\/doi.org\/10.3892\/br.2021.1457.","journal-title":"Biomed Rep"},{"key":"9728_CR87","doi-asserted-by":"publisher","unstructured":"Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, Kivitz A, Sherrer Y, Pucino F, Csako G, Costello R, Pham TH, Snyder C, van der Heijde D, Tao X, Wesley R, Lipsky PE. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med. 2009;151:229\u2013240, w249-251. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00005.","DOI":"10.7326\/0003-4819-151-4-200908180-00005"},{"key":"9728_CR88","doi-asserted-by":"publisher","unstructured":"Chen E, Wang L, Wang Q, Cai Y, Dou Y, Qu H, Zhu J, Zhao H, Zheng S, Zhao C, Chen B. Triptolide alleviates psoriasis through inhibiting the Wnt5a\/\u03b2-Catenin signaling pathway.\u00a0Front Pharmacol. 2025;16. https:\/\/doi.org\/10.3389\/fphar.2025.1534118.","DOI":"10.3389\/fphar.2025.1534118"},{"key":"9728_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004334","volume":"4","author":"R Chugh","year":"2012","unstructured":"Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM, Saluja AK. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012;4. https:\/\/doi.org\/10.1126\/scitranslmed.3004334.","journal-title":"Sci Transl Med"},{"key":"9728_CR90","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.tips.2019.03.002","volume":"40","author":"P Noel","year":"2019","unstructured":"Noel P, Von Hoff DD, Saluja AK, Velagapudi M, Borazanci E, Han H. Triptolide and its derivatives as cancer therapies. Trends Pharmacol Sci. 2019;40:327\u201341. https:\/\/doi.org\/10.1016\/j.tips.2019.03.002.","journal-title":"Trends Pharmacol Sci"},{"key":"9728_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4299","volume":"32","author":"J Zhao","year":"2018","unstructured":"Zhao J, Xie C, Mu X, Krausz KW, Patel DP, Shi X, Gao X, Wang Q, Gonzalez FJ. Metabolic alterations in triptolide-induced acute hepatotoxicity. Biomed Chromatogr. 2018;32. https:\/\/doi.org\/10.1002\/bmc.4299.","journal-title":"Biomed Chromatogr"},{"key":"9728_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.811850","volume":"12","author":"D Kang","year":"2022","unstructured":"Kang D, Liu Y, Song Y, Fang B, Zhang Q, Hu L. Triptolide shows high sensitivity and low toxicity against acute myeloid leukemia cell lines through inhibiting WSTF-RNAPII complex. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.811850.","journal-title":"Front Oncol"},{"key":"9728_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110084","volume":"126","author":"J Fu","year":"2020","unstructured":"Fu J, Zang Y, Zhou Y, Chen C, Shao S, Hu M, Shi G, Wu L, Zhang D, Zhang T. A novel triptolide derivative ZT01 exerts anti-inflammatory effects by targeting TAK1 to prevent macrophage polarization into pro-inflammatory phenotype. Biomed Pharmacother. 2020;126. https:\/\/doi.org\/10.1016\/j.biopha.2020.110084.","journal-title":"Biomed Pharmacother"},{"key":"9728_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1021\/jm00271a017","volume":"15","author":"SM Kupchan","year":"1972","unstructured":"Kupchan SM, Bondesson G, Davies AP. Tumor inhibitors. 70. Structure-cytotoxicuty relations among N-acyltriamines related to solapalmitine. J Med Chem. 1972;15:65\u20138. https:\/\/doi.org\/10.1021\/jm00271a017.","journal-title":"J Med Chem"},{"key":"9728_CR95","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00280-014-2428-6","volume":"73","author":"JM Fidler","year":"2014","unstructured":"Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014;73:961\u201374. https:\/\/doi.org\/10.1007\/s00280-014-2428-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9728_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2487-7","volume":"16","author":"TA Reno","year":"2016","unstructured":"Reno TA, Tong SW, Wu J, Fidler JM, Nelson R, Kim JY, Raz DJ. The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer. BMC Cancer. 2016;16(1). https:\/\/doi.org\/10.1186\/s12885-016-2487-7.","journal-title":"BMC Cancer"},{"issue":"3","key":"9728_CR97","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/leu.2011.246","volume":"26","author":"BZ Carter","year":"2012","unstructured":"Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 2012;26(3):443\u201350. https:\/\/doi.org\/10.1038\/leu.2011.246.","journal-title":"Leukemia"},{"key":"9728_CR98","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.2147\/dddt.S467929","volume":"18","author":"M Jiang","year":"2024","unstructured":"Jiang M, Xie Y, Wang P, Du M, Wang Y, Yan S. Research progress of triptolide against fibrosis. Drug Des Devel Ther. 2024;18:3255\u201366. https:\/\/doi.org\/10.2147\/dddt.S467929.","journal-title":"Drug Des Devel Ther"},{"key":"9728_CR99","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ejmech.2019.05.032","volume":"176","author":"W Hou","year":"2019","unstructured":"Hou W, Liu B, Xu H. Triptolide: medicinal chemistry, chemical biology and clinical progress. Eur J Med Chem. 2019;176:378\u201392. https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.032.","journal-title":"Eur J Med Chem"},{"key":"9728_CR100","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/aps.2012.88","volume":"33","author":"DD Wu","year":"2012","unstructured":"Wu DD, Huang L, Zhang L, Wu LY, Li YC, Feng L. LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression. Acta Pharmacol Sin. 2012;33:1187\u201394. https:\/\/doi.org\/10.1038\/aps.2012.88.","journal-title":"Acta Pharmacol Sin"},{"key":"9728_CR101","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.biopha.2014.05.002","volume":"68","author":"M Li","year":"2014","unstructured":"Li M, Wang Xe, Liu M, Qi X, Li J. NF-\u03baB signaling inhibition and anticancer activities of LLDT-246 on human colorectal cancer HCT-116 cells in vitro. Biomed Pharmacother. 2014;68:527\u201335. https:\/\/doi.org\/10.1016\/j.biopha.2014.05.002.","journal-title":"Biomed Pharmacother"},{"key":"9728_CR102","doi-asserted-by":"publisher","first-page":"10181","DOI":"10.26355\/eurrev_202311_34294","volume":"27","author":"LS Zeng","year":"2023","unstructured":"Zeng LS, Yang P, Qin YY, He WH, Cao L. Pharmacological activity and clinical progress of triptolide and its derivatives LLDT-8, PG490-88Na, and Minnelide: a narrative review. Eur Rev Med Pharmacol Sci. 2023;27:10181\u2013203. https:\/\/doi.org\/10.26355\/eurrev_202311_34294.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"9728_CR103","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.biopha.2017.06.041","volume":"93","author":"H Xu","year":"2017","unstructured":"Xu H, Fan X, Zhang G, Liu X, Li Z, Li Y, Jiang B. LLDT-288, a novel triptolide analogue exhibits potent antitumor activity in vitro and in vivo. Biomed Pharmacother. 2017;93:1004\u20139. https:\/\/doi.org\/10.1016\/j.biopha.2017.06.041.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"9728_CR104","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0002-9440(10)64046-1","volume":"158","author":"G Krishna","year":"2001","unstructured":"Krishna G, Liu K, Shigemitsu H, Gao M, Raffin TA, Rosen GD. PG490-88, a derivative of triptolide, blocks Bleomycin-induced lung fibrosis. Am J Pathol. 2001;158(3):997\u20131004. https:\/\/doi.org\/10.1016\/S0002-9440(10)64046-1.","journal-title":"Am J Pathol"},{"key":"9728_CR105","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1097\/00007890-200011270-00008","volume":"70","author":"BJ Chen","year":"2000","unstructured":"Chen BJ, Liu C, Cui X, Fidler JM, Chao NJ. Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. Transplantation. 2000;70:1442\u20137. https:\/\/doi.org\/10.1097\/00007890-200011270-00008.","journal-title":"Transplantation"},{"key":"9728_CR106","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11101-025-10172-z","volume":"2","author":"JM Fidler","year":"2003","unstructured":"Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M, Rosen GD. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther. 2003;2:855\u201362. https:\/\/doi.org\/10.1007\/s11101-025-10172-z.","journal-title":"Mol Cancer Ther"},{"key":"9728_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217041","volume":"597","author":"SH Lim","year":"2024","unstructured":"Lim SH, Saluja A, Vickers S, Hong JY, Kim ST, Lavania S, Pandey S, Gupta VK, Velagapudi MR, Lee J. The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: a phase I trial. Cancer Lett. 2024;597. https:\/\/doi.org\/10.1016\/j.canlet.2024.217041.","journal-title":"Cancer Lett"},{"key":"9728_CR108","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jep.2013.08.018","volume":"150","author":"XM Zhuang","year":"2013","unstructured":"Zhuang XM, Liu PX, Zhang YJ, Li CK, Li Y, Wang J, Zhou L, Zhang ZQ. Simultaneous determination of triptolide and its prodrug MC002 in dog blood by LC-MS\/MS and its application in pharmacokinetic studies. J Ethnopharmacol. 2013;150:131\u20137. https:\/\/doi.org\/10.1016\/j.jep.2013.08.018.","journal-title":"J Ethnopharmacol"},{"key":"9728_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107472","volume":"94","author":"J Fu","year":"2021","unstructured":"Fu J, Zang Y, Zhou Y, Chen C, Shao S, Shi G, Wu L, Zhu G, Sun T, Zhang D, Zhang T. Exploring a novel triptolide derivative possess anti-colitis effect via regulating T cell differentiation. Int Immunopharmacol. 2021;94. https:\/\/doi.org\/10.1016\/j.intimp.2021.107472.","journal-title":"Int Immunopharmacol"},{"key":"9728_CR110","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12305","volume":"27","author":"X Ding","year":"2024","unstructured":"Ding X, Liu J, Sun Y, Chen X. Triptolide alleviates the development of inflammation in ankylosing spondylitis via the NONHSAT227927.1\/JAK2\/STAT3 pathway. Exp Ther Med. 2024;27. https:\/\/doi.org\/10.3892\/etm.2023.12305.","journal-title":"Exp Ther Med"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09728-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-025-09728-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09728-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:29:03Z","timestamp":1770190143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-025-09728-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9728"],"URL":"https:\/\/doi.org\/10.1007\/s12026-025-09728-0","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}